11 citations
,
June 2005 in “Postgraduate Medical Journal”
This case report details an instance of transient scrotalhair development in a UK infant, which spontaneously resolved by 7 months of age, with no underlying pathology identified.
This review describes how male hypogonadism can lead to various skin and hair symptoms, as well as potential dermatological reactions to hormone treatments and reports no new clinical results.
17 citations
,
May 1969 in “American Journal of Physical Anthropology”
This study describes unique anatomical characteristics of the skin and hair structures in the silver marmoset, including features such as thin epidermis, specialized nerve end-organs, and distinctive gland compositions.
75 citations
,
January 1995 in “American journal of primatology”
In this study, seasonal hair loss was most pronounced in low-ranking male vervet monkeys, and changes in scrotal color and hyperpigmentation also correlated with hair loss, but underlying causes were not identified.
Finasteride is used for hair loss, with mixed reports of no side effects and claims of long-term negative effects known as Post Finasteride Syndrome (PFS). The conversation debates the existence and causes of PFS, with differing opinions on whether it is psychological or real.
Finasteride can affect sperm quality, but fertility usually returns after stopping it, as shown by a user who conceived four months after discontinuation. Some users successfully conceive while on finasteride, though some prefer to pause its use to minimize risks.
A 35-year-old male used oral finasteride and topical minoxidil, later transitioning to oral minoxidil, to stop hair loss and improve hair density. He plans a future hair transplant and experienced temporary libido changes but no permanent side effects.
Stopping minoxidil and replacing it with PP405 might lead to hair regrowth, but the effectiveness of PP405 is uncertain as it is still being tested. Minoxidil and PP405 work differently, with minoxidil increasing blood flow and PP405 affecting follicle metabolism.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.